Trial Profile
A Multicenter, Single-Arm, Open-Label Study With Pomalidomide in Combination With Low Dose Dexamethasone in Subjects With Refractory or Relapsed and Refractory Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Mar 2022
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary) ; Pomalidomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Registrational
- Acronyms STRATUS
- Sponsors Celgene Corporation
- 14 Jan 2021 Results of a pooled analysis (of data extracted from NCT01712789, NCT02773030, NCT01421524, NCT01191060 studies and Myeloma Genome Project) assessing multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma published in the Blood
- 04 Aug 2020 Results (n=1110) of a comprehensive analysis assessing Cereblon changes from DNA and RNA samples extracted from myeloma cells and peripheral blood germline DNA collected at baseline and relapse from patients enrolled in four clinical studies: CC4074-MM010, CC220-MM001, CC122-ST-001MM2, IFM/DFCI-2009 and Myeloma Genome Project published in the Blood
- 05 May 2020 Status changed from active, no longer recruiting to completed.